Drug Trial Radar · NCT05231785
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 4, 2022
Primary completion
Jan 11, 2029
Study completion Jan 11, 2029
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Feb 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.
Conditions
- Early-Onset Alzheimer Disease
Interventions
ALN-APPDrug
ALN-APP will be administered intrathecally (IT)
PlaceboDrug
Placebo will be administered IT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Frequency of Adverse EventsTime frame: Up to 12 months
- Part B: Frequency of Adverse EventsTime frame: Up to 42 months
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Trial Site
La Jolla, California · Completed
Clinical Trial Site
Indianapolis, Indiana · Recruiting
Clinical Trial Site
Montreal, Canada · Recruiting
Clinical Trial Site
Toronto, Canada · Recruiting
Clinical Trial Site
Amsterdam, Netherlands · Recruiting
Clinical Trial Site
Groningen, Netherlands · Completed
Clinical Trial Site
Huntley Street, United Kingdom · Recruiting
Clinical Trial Site
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.